NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031240175

Registered date:19/06/2024

Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedGeneralized Myasthenia Gravis
Date of first enrollment17/06/2024
Target sample size240
Countries of recruitmentUnited States,Japan,United Kingdom,Japan,Taiwan,Japan,Korea,Japan,Georgia,Japan,Brazil,Japan,Australia,Japan,Argentina,Japan,France,Japan,Germany,Japan,Italy,Japan,Spain,Japan,Poland,Japan
Study typeInterventional
Intervention(s)This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Participants will be randomly assigned in a ratio of 1:1:1 to 3 arms. Placebo Arm: - DBPC Period: Participants will be administered with Placebo, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5. - BE Period: Participants initially randomized to placebo matched to cladribine in DBPC period will receive cladribine Low Dose or High Dose, orally as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated if clinically justified with placebo matched to cladribine. - RT Period: Participants requiring retreatment with cladribine Low Dose or High Dose or retreated with cladribine supplemental dose if clinically justified. Cladribine Low Dose Arm: - DBPC Period: Participants will be administered with cladribine Low Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5. - BE Period: Participants initially randomized to cladribine Low Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified. - RT Period: Participants requiring retreatment with cladribine Low Dose regimen and/or supplemental dose will receive the selected dose of cladribine if clinically justified. Cladribine High Dose Arm: - DBPC Period: Participants will be administered cladribine High Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5. - BE Period: Participants initially randomized to cladribine High Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified. - RT Period: Participants requiring retreatment with cladribine High Dose regimen and/or supplemental dose will receive the selected dose of cladribine if clinically justified.

Outcome(s)

Primary OutcomeChange from Baseline in Myasthenia Gravis - Activities of Daily Living (MG- ADL) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria-Adults of:18 years of age at the time of signing the informed consent. -Diagnosis of Myasthenia Gravis with generalized muscle weakness, meeting clinical criteria for Myasthenia Gravis Foundation of America Class II to !Va classification. - In participants positive for Acetylcholine receptor antibody (anti- AChR) or muscle-specific kinase antibody(anti-MuSK) - In participants that are autoantibody seronegative and participants who are positive for anti-low-density lipoprotein receptor- related protein 4 antibodies (anti-LRP4) -Has a Screening and Baseline MG-ADL score more than or equal to (>=) 6 with at least 50 percentage(%) of the total score due to non- ocular symptoms -If treated with oral corticosteroids: should be on a stable daily dose for at least 4 weeks before randomization. In such case, the daily dose of oral steroids should not exceed 20 milligrams(mg)/day for prednisone/ prednisolone or 16 mg/day for methylprednisolone -If treated with acetylcholinesterase inhibitor should be on a stable daily dose for at least 4 weeks before randomization -Have a body weight >= 40 kilograms -Other protocol defined inclusion criteria could apply
Exclude criteria-Immunologic disorder other than MG or any other condition requiring chronic oral, intravenous, intramuscular, or intraarticular corticosteroid therapy. Well-controlled thyroid disease, as per the Treating Investigator or the participants regular treating physician recorded in the source documents, is not exclusionary -Molecularly characterized or suspected congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, inherited myopathy, muscular dystrophy, acquired myopathy or any other neurologic or systematic disease that mimics MG muscular weakness -Active, clinically significant viral, bacterial, or fungal infection, including brain MRI findings consistent with signs of infection such as PML, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before or during Screening, or completion of oral antiinfectives within 2 weeks before or during Screening, or a history of recurrent infections (i.e. 3 or more of the same type of infection in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary. -Has a history of or current diagnosis of active tuberculosis (TB) -Active malignancy, or history of cancer -Treatment with nonsteroidal immunosuppressants, used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus within 4 weeks prior to randomization -Treatment with eculizumab, rozanolixizumab efgartigimod, ravulizumab, or zilucoplan within 8 weeks prior to randomization -History of thymectomy within 6 months prior to Screening. -History of generalized seizures (except for history of infantile febrile seizures). -Negative for Varicella Zoster Virus antibodies at screening. -Other protocol defined exclusion criteria could apply

Related Information

Contact

Public contact
Name Kyoko Ishii
Address 1-8-1 Shimomeguro, Meguro-ku, Tokyo Tokyo Japan 153-8926
Telephone +81-3-6756-0800
E-mail MBJ_clinicaltrial_information@merckgroup.com
Affiliation Merck Biopharma Co., Ltd.
Scientific contact
Name Kyoko Ishii
Address 1-8-1 Shimomeguro, Meguro-ku, Tokyo Tokyo Japan 153-8926
Telephone +81-3-6756-0800
E-mail MBJ_clinicaltrial_information@merckgroup.com
Affiliation Merck Biopharma Co., Ltd.